These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 1997702

  • 1. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.
    Johansson JE, Andersson SO, Holmberg L, Bergström R.
    J Urol; 1991 Mar; 145(3):519-22; discussion 522-3. PubMed ID: 1997702
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R, Nordle O, Josefsson K.
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
    Hedlund PO, Henriksson P.
    Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Correlation of pretreatment plasma levels of estradiol and sex-hormone-binding globulin-binding capacity with clinical stage and survival of patients with prostatic cancer.
    Haapiainen R, Rannikko S, Adlercreutz H, Alfthan O.
    Prostate; 1986 Mar; 8(2):127-37. PubMed ID: 3952023
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R, Sundin T, Colleen S, Lindstedt E, Wadström L, Carlsson S, Hellsten S, Pompeius R, Holmquist B, Nilsson T.
    Scand J Urol Nephrol; 1986 Mar; 20(2):101-5. PubMed ID: 3529368
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.
    Mikkola A, Aro J, Rannikko S, Ruutu M, Finnprostate Group.
    Prostate; 2007 Mar 01; 67(4):447-55. PubMed ID: 17219379
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.
    Henriksson P, Edhag O, Eriksson A, Johansson SE.
    Br J Urol; 1989 Feb 01; 63(2):186-90. PubMed ID: 2649197
    [Abstract] [Full Text] [Related]

  • 20. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC, Hammar M, Lindberg B, Spångberg A, Varenhorst E, Scandinavian Prostatic Cancer Group-5 Trial Study.
    J Urol; 2001 Aug 01; 166(2):517-20. PubMed ID: 11458057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.